Glioma
Conditions
Brief summary
establishment of glioma microenvironment cell dynamic evolution database reveal the mechanism of GIM promoting malignant transformation of glioma cells reveal the dynamic regulation process of immune cells in the process of glioma evolution
Detailed description
To collect tissue samples from different stages of glioma evolution and establish a high-quality high-throughput sequencing database of immune microenvironment cells, so as to lay a data foundation for later mining the dialogue mechanism and key targets between immune cells and tumor cells in glioma microenvironment. Based on the analysis results of the above database, the key role of key target molecules in the dialogue between GIM and glioma cells and the regulation ability of immune cells in the immune microenvironment were confirmed through cell and mouse animal experiments, which laid the foundation for later targeted drug research and development. Combined with fluorescence imaging technology, through in vivo imaging of mice, it can provide more intuitive and effective visual verification for the dynamic infiltration process of GIM and other immune microenvironment cells in the process of glioma evolution, and provide a new theoretical basis for the visualization research of dynamic regulation of glioma immune microenvironment cells.
Interventions
PROCEDUREsurgery
surgery
Sponsors
Huashan Hospital
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled 1. They were 18-80 years old, male and female; 2. The pathological results of frozen section during operation were gliomas (20 cases of who grade II, II and IV, respectively); 3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis; 4. Sign informed consent.
Exclusion criteria
* Patients who meet any of the following criteria will not be included in this study: 1. Participants in other clinical trials; 2. Pregnant women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Multi-omics characteristics of glioma patients | 24 month | we aim to describe patient's features about transcriptomics 、Immunomics、Radiomics ，etc. |
| expression level of protein，drived from paraffin-embedded specimens， retrospectively collected. | 24 month | different expression level of proteins in Gliomas with different grades and molecular subgroups (500 cases) |
Countries
China
Contacts
Primary ContactYu Yao
Outcome results
None listed